Prostate and breast cancers, which are hormone-dependant cancers, are highly frequent (up to 1/3 of cancers in male, 1/3 of cancers in female patients) and often multifocal. Multifocality, in particular, rings the bell of a specific carcinogenetic agent (such as heritability is in retinoblastoma). Here we point a highly uneven distribution of genetic events (translocation breakpoints) in prostate and breast cancers, which favours the hypothesis of cooperation between viruses and hormone receptors to cut DNA at high rates, delete parts of it, facilitating oncogene translocations and oncogenesis. If our hypothesis turns out to be right, vaccination against breast cancer and prostate cancer might notably diminish the frequency of these cancers.
Looking at chromosomal rearrangements in prostate adenocarcinoma, using the Atlas of Genetics and Cytogenetics in Oncology and Haematology (Huret et al., 2003) , the Mitelman Database (Mitelman et al., 2012) , and Goldenpath (Fujita et al., 2011) (http://atlasgeneticsoncology.org/, http://cgap.nci. nih.gov/Chromosomes/Mitelman, and http://genome.ucsc.edu/ respectively), we noted that, out of 42 relevant rearrangements available in early 2011, 10 exhibited the two partner breakpoints in the same chromosome band (e.g. 5q31 fused to 5q31). Given that 312 chromosome bands are at risk of rearrangement, the probability of the observed distribution is p=1.5 x 10 -16 (binomial distribution).
Such a non random close proximity of the two partner breakpoints is even more striking at the base level (e.g. 6 kb in the 5q31-5q31 rearrangement; see Table 1 ). The situation is very similar with breast adenocarcinoma: Of 39 rearrangements, 20 have breakpoints in close proximity ( Table 2 ). The probability of such an event is p=6 x 10 -39 . We herein uncover a highly significant non random distribution of breakpoints in breast and prostate cancer DNA rearragements and microdeletions (by comparison, only 1 of 10 rearrangements in lung adenocarcinoma exhibit both breakpoints in the same band (R3HDM2/NFE2 in the del(12)(q13q13)). A bias of publications may exist, but cannot account for such a highly unexpected finding. PIK3C2A/TEAD1 del(11)(p15p15) 17108126 12695969 4,4 Mb Note. These fusion genes were first described in Tomlins et al., 2005; Maher et al., 2009a; et al., 2009b; Rickman et al., 2009 . (Cato et al., 1987; Pogo et al., 2010) . A retrovirus containing androgen response elements remains to be found, since the candidate, XMRV, appears now to be of experimental recombinant origin ( Paprotka et al., 2011) . Both androgen and estrogen receptors induce DNA double strands breaks (DSBs) (Lin et al., 2009, Williamson and Lees-Miller, 2011) ; such DSBs can seed the formation of genomic/chromosome rearrangements, and, at random, the possible junction of oncogene loci normally separated , Mani et al., 2009 . It has been found that androgen receptor signaling and topoisomerase II mediate DSBs and TMPRSS2-ERG rearrangements in prostate cancer (Haffner et al., 2010) . In case of a TMPRSS2-ERG rearrangement, a deletion of 3 mb occurs (Table 1) . HMTV is found in 40% of breast cancers in American women, in 60% of milk from patients with a history of breast cancer and in 5% of milk from normal subjects (cited in Pogo et al., 2010) . HMTV/MMTV sequences and enhanced Wnt-1 expression were found in breast ductal carcinoma (Lawson et al., 2010) . However, other viruses may be implicated, and it must be kept in mind that HBV, HPV, EBV, CMV have also been found to be associated with breast cancer. There is no reason a priori for an organ to fall "too" frequently into a cancerous process in the absence of an additional carcinogenetic agent. In skin cancer, ultraviolet radiation is the known major helper, and lung cancer is a rare cancer without a history of smoking. The "abnormally" high frequency of prostate and breast cancers may well be due to this association in crime of viruses and hormone receptors. If our hypothesis turns to be right, inhibitors for androgens/estrogens receptors and vaccination against breast cancer prostate cancer (as it is now available for cervix cancer / papilloma virus) might abrogate an important proportion of DSBs, and notably diminish the frequency of these cancers and/or facilitate their cure.
